Veracyte Inc Total Assets
Veracyte Inc total assets. Based on the latest financial reports, Veracyte Inc (VCYT) holds total assets worth $1.49 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Veracyte Inc worth for the company's overall valuation and market capitalisation.
Total Assets of Veracyte Inc (2011–2025)
Total assets of Veracyte Inc from 2011 to 2025. This chart illustrates how Veracyte Inc's total assets have evolved over time, based on quarterly financial data. See Veracyte Inc stock price for real-time trading data and today's change.
Veracyte Inc - Asset Composition Analysis
Veracyte Inc Total Assets Breakdown (December 2025)
Veracyte Inc total assets breakdown as of December 2025. Veracyte Inc's total assets of $1.49 Billion consist of 34.7% current assets and 65.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 25.8% |
| Accounts Receivable | $44.66 Million | 3.2% |
| Inventory | $20.55 Million | 1.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $89.15 Million | 6.3% |
| Goodwill | $767.15 Million | 54.6% |
Asset Composition Trend (2011–2025)
This chart illustrates how Veracyte Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of Veracyte Inc to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Veracyte Inc's current assets represent 34.7% of total assets in 2025, a decrease from 82.2% in 2011.
- Cash Position: Cash and equivalents constituted 25.8% of total assets in 2025, down from 72.4% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 60.0% of total assets, an increase from 0.0% in 2011.
- Asset Diversification: The largest asset category is goodwill at 54.6% of total assets.
Veracyte Inc Competitors by Total Assets
Key competitors of Veracyte Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Lonza Group AG
SW:LONN
|
Switzerland | CHF18.26 Billion |
|
Revvity Inc.
NYSE:RVTY
|
USA | $12.00 Billion |
|
Dr. Lal Path Labs Ltd.
NSE:LALPATHLAB
|
India | Rs31.46 Billion |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
|
China | CN¥9.20 Billion |
|
Cowealth Medical China Co.Ltd.
SHG:603122
|
China | CN¥1.42 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Prodia Widyahusada Tbk PT
JK:PRDA
|
Indonesia | Rp2.57 Trillion |
|
Scope Fluidics SA
WAR:SCP
|
Poland | zł141.67 Million |
Veracyte Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.16 | 5.43 | 4.58 |
| Quick Ratio | 8.80 | 5.10 | 4.39 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $512.04 Million | $338.25 Million | $179.27 Million |
Veracyte Inc - Advanced Valuation Insights
This section examines the relationship between Veracyte Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.54 |
| Latest Market Cap to Assets Ratio | 2.40 |
| Asset Growth Rate (YoY) | 8.2% |
| Total Assets | $1.41 Billion |
| Market Capitalization | $3.38 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Veracyte Inc's assets at a significant premium (2.40x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Veracyte Inc's assets grew by 8.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Veracyte Inc (2011–2025)
The table below shows the annual total assets of Veracyte Inc from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.41 Billion | +8.15% |
| 2024-12-31 | $1.30 Billion | +16.60% |
| 2023-12-31 | $1.11 Billion | -3.59% |
| 2022-12-31 | $1.16 Billion | -2.64% |
| 2021-12-31 | $1.19 Billion | +159.83% |
| 2020-12-31 | $457.16 Million | +66.11% |
| 2019-12-31 | $275.21 Million | +128.13% |
| 2018-12-31 | $120.64 Million | +53.35% |
| 2017-12-31 | $78.67 Million | -22.14% |
| 2016-12-31 | $101.03 Million | +34.20% |
| 2015-12-31 | $75.28 Million | +16.11% |
| 2014-12-31 | $64.84 Million | -18.57% |
| 2013-12-31 | $79.63 Million | +317.63% |
| 2012-12-31 | $19.07 Million | +82.44% |
| 2011-12-31 | $10.45 Million | -- |
About Veracyte Inc
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test… Read more